Home/Pipeline/ENA101 (targeting DARKFOX)

ENA101 (targeting DARKFOX)

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Enara Bio

About Enara Bio

Enara Bio is an emerging private biotech founded in 2019, leveraging its proprietary EDAPT® and EnTiCE® platforms to discover novel Dark Antigens and develop bispecific T-cell engagers for solid tumors. The company has secured backing from prominent investors and a strategic collaboration with Boehringer Ingelheim, validating its approach. Its lead program, ENA101, is in late preclinical development, with plans to enter First-in-Human studies, positioning it as a potential first-in-class therapy.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed